The p53 network in head and neck cancer.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and, despite advances in treatment, still represents a clinical challenge. Inactivation of one or more components of the p53 network is an extremely common event in human neoplasia. In HNSCC, disabling of p53 occurs in a high proportion of cases by mutation in the p53 gene, but other mechanisms of inactivation, such as the presence of human papillomavirus (HPV) and molecular abnormalities in other components of the pathway, are also recognised. The frequent changes occurring in the p53 pathway in HNSCC imply that molecular genetic and immunocytochemical analysis of this critical tumour suppressor network may be of diagnostic and prognostic utility in the clinical management of HNSCC. Further, these changes also provide targets for the development of novel therapeutic approaches to this increasingly common cancer, in which clinical cure for advanced disease remains an elusive goal.

[1]  R H Hruban,et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[2]  C. Ostwald,et al.  p53 mutational spectra are different between squamous‐cell carcinomas of the lip and the oral cavity , 2000, International journal of cancer.

[3]  C. Bradford,et al.  Predictive factors in head and neck cancer. , 1999, Hematology/oncology clinics of North America.

[4]  E. Dellambra,et al.  Downregulation of 14-3-3σ Prevents Clonal Evolution and Leads to Immortalization of Primary Human Keratinocytes , 2000, The Journal of cell biology.

[5]  K. Mancer,et al.  Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma , 2001, Oncogene.

[6]  J. Bourhis,et al.  Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.

[7]  R. Hruban,et al.  The incidence of p53 mutations increases with progression of head and neck cancer. , 1993, Cancer research.

[8]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[9]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[10]  E. Androphy,et al.  AMF1 (GPS2) Modulates p53 Transactivation , 2001, Molecular and Cellular Biology.

[11]  G. Sanguineti,et al.  Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. , 1992, The New England journal of medicine.

[12]  B. Gusterson,et al.  Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia , 2002, Oncogene.

[13]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[14]  W. El-Deiry,et al.  BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets , 2002, Molecular and Cellular Biology.

[15]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[16]  A. Flahault,et al.  p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[18]  J. Overgaard,et al.  TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[20]  Yoichi Taya,et al.  Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.

[21]  J. Y. Park,et al.  p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. , 1998, Carcinogenesis.

[22]  T. McDonnell,et al.  Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. , 1995, Cancer research.

[23]  S. Franceschi,et al.  Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aero‐digestive tract , 1995, International journal of cancer.

[24]  M. Gentile,et al.  Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis , 2001, Oncogene.

[25]  W. Foulkes,et al.  No association betweenP53codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck , 2000, British Journal of Cancer.

[26]  W. Lam,et al.  Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[27]  D. Brachman,et al.  Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. , 1992, Cancer research.

[28]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[29]  S. Berger,et al.  p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage , 1999, Molecular and Cellular Biology.

[30]  D. Spandidos,et al.  p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. , 1997, Cancer research.

[31]  C. Harris,et al.  Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. , 2000, Mutation research.

[32]  Z. Hao,et al.  p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy , 1997, Oncogene.

[33]  D. Pim,et al.  Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.

[34]  Hongbing Shen,et al.  P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. , 2002, Cancer letters.

[35]  Giulia Piaggio,et al.  Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.

[36]  F. Bosch,et al.  TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.

[37]  A. Malliri,et al.  Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. , 1991, British Journal of Cancer.

[38]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[39]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Schönthal,et al.  Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1 , 2001, Oncogene.

[41]  D. Johnston,et al.  High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma , 2000, Oncogene.

[42]  K. Sugimachi,et al.  p53 polymorphism in human papillomavirus-associated esophageal cancer. , 2000, Cancer research.

[43]  F. Apiou,et al.  hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  G. Bradley,et al.  p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas , 2000, The Journal of pathology.

[45]  J. Walboomers,et al.  p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck , 1997, International journal of cancer.

[46]  T. Pandita,et al.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Reiss,et al.  Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization. , 1995, Gene.

[48]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[49]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Laurent-Puig,et al.  Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. , 2000, Cancer research.

[51]  E. Appella,et al.  p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* , 2000, The Journal of Biological Chemistry.

[52]  C. R. Leemans,et al.  Multiple head and neck tumors frequently originate from a single preneoplastic lesion. , 2002, The American journal of pathology.

[53]  D. Sidransky,et al.  Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. , 1999, Human pathology.

[54]  A. Kropveld,et al.  Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[55]  S. Goodman,et al.  p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.

[56]  B. Gusterson,et al.  Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. , 2002, Cancer research.

[57]  G. Snow,et al.  p53 immunoexpression in non‐malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management , 2000, The Journal of pathology.

[58]  Wei Gu,et al.  Synergistic activation of transcription by CBP and p53 , 1997, Nature.

[59]  L. Turek,et al.  p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[60]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[61]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[62]  T. Soussi,et al.  Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients , 2000, The Journal of pathology.

[63]  G. Snow,et al.  p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma , 1998, The Journal of pathology.

[64]  Å. Borg,et al.  p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. , 1998, British Journal of Cancer.

[65]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[66]  P. Beaune,et al.  p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[68]  O. Gallo,et al.  Cumulative prognostic value of p53 mutations and bcl‐2 protein expression in head‐and‐neck cancer treated by radiotherapy , 1999, International journal of cancer.

[69]  R. Iggo,et al.  Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. , 2001, Carcinogenesis.

[70]  P. Hainaut,et al.  TP53 mutations and MDM2 gene amplification in squamous‐cell carcinomas of the esophagus in South Thailand , 2000, International journal of cancer.

[71]  D. Sidransky,et al.  Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.

[72]  M. Gulley,et al.  Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .

[73]  I. Ganly,et al.  p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy , 2000, British Journal of Cancer.

[74]  S. Riethdorf,et al.  P53-mutation in smears of oral squamous cell carcinoma. , 2000, Anticancer research.

[75]  K. Cullen,et al.  Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging , 2000, Current opinion in oncology.

[76]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[77]  R. Ralhan,et al.  MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. , 1999, Oral oncology.

[78]  G. Casey,et al.  Frequent p53 mutations in head and neck cancer. , 1992, Cancer research.

[79]  J. Langdon,et al.  Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  T. Wendt,et al.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  E. Vokes,et al.  The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. , 2000, Seminars in oncology.

[82]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[83]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[85]  M. Tang,et al.  Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers , 1998, Oncogene.

[86]  Francesca Storici,et al.  Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.